Consensus Eli Lilly and Company

Equities

LLY

US5324571083

Market Closed - Nyse 04:00:02 2024-03-01 pm EST 5-day change 1st Jan Change
782.1 USD +3.77% Intraday chart for Eli Lilly and Company +1.63% +34.17%

Evolution of the average Target Price on Eli Lilly and Company

Price target over the last 5 years

History of analyst recommendation changes

0d61710f3cb43feef.EN3jvcalDDRI_Fgurk0G7469VZJmNizyxDa2qVs42bU.IZiR14DgU24fuywY9Dpnid_SPsAkTx-HlWeBxzhPhoRP5Yrys5ZZRgaLAQ~42cd8c60da6b547da5baca7e121befc4
BofA Securities Hikes Price Target on Eli Lilly to $1,000 From $800 Citing Tirzepatid Label Expansion, Keeps Buy Rating MT
ANALYST RECOMMENDATIONS : Domino's pizza, WPP, PPG, Workday, Eli Lilly... Our Logo
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox... Our Logo
DZ Bank Downgrades Eli Lilly to Hold From Buy, Raises Price Target to $820 From $790 MT
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever.... Our Logo
China move leaves markets unfazed Our Logo
Forget about rate cuts... Our Logo
Morgan Stanley Raises Price Target on Eli Lilly to $950 From $805, Keeps Overweight Rating MT
ANALYST RECOMMENDATIONS : Coinbase, Comcast, Eli Lilly, Nvidia, Uber... Our Logo
ELI LILLY AND COMPANY : Jefferies keeps its Buy rating ZD
Deutsche Bank Adjusts Eli Lilly and Co. Price Target to $695 From $535, Maintains Hold Rating MT
ANALYST RECOMMENDATIONS : Doordash, Microsoft, Roblox, Uber, Redrow... Our Logo
UBS Adjusts Eli Lilly and Co. Price Target to $810 From $710, Maintains Buy Rating MT
BofA Securities Raises Price Target on Eli Lilly to $800 From $750, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Eli Lilly to $805 From $763, Maintains Overweight Rating MT
Fed officials fail to convince investors, who are focused on earnings Our Logo
Wells Fargo Adjusts Eli Lilly and Co.'s Price Target to $825 From $700, Keeps Overweight Rating MT
Cantor Fitzgerald Adjusts Eli Lilly and Co.'s Price Target to $815 From $630, Keeps Overweight Rating MT
Jefferies Adjusts Eli Lilly and Co.'s Price Target to $814 From $768, Keeps Buy Rating MT
Morningstar Adjusts Eli Lilly and Co.'s Price Target to $500 From $450, Keeps Sell Rating MT
JPMorgan Adjusts Eli Lilly and Co.'s Price Target to $775 From $650, Keeps Overweight Rating MT
Truist Adjusts Eli Lilly and Co.'s Price Target to $850 From $650, Keeps Buy Rating MT
BMO Capital Adjusts Eli Lilly and Co.'s Price Target to $865 From $710, Keeps Outperform Rating MT
Wolfe Research Adjusts Eli Lilly and Co.'s Price Target to $813 From $690, Keeps Outperform Rating MT
Barclays Adjusts Eli Lilly and Co.'s Price Target to $810 From $680, Keeps Overweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
782.1 USD
Average target price
767.6 USD
Spread / Average Target
-1.86%
High Price Target
1,000 USD
Spread / Highest target
+27.86%
Low Price Target
500 USD
Spread / Lowest Target
-36.07%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Eli Lilly and Company

BofA Securities
DZ Bank
Morgan Stanley
JEFFERIES Akash Tewari
Deutsche Bank Securities
UBS
Barclays
Wells Fargo Securities
Cantor Fitzgerald
Jefferies & Co.
Morningstar
JPMorgan Chase
Truist Securities
BMO Capital
Wolfe Research
Guggenheim
Goldman Sachs
Daiwa Securities
Berenberg Bank
Citigroup
Argus
Credit Suisse
HSBC
TD Cowen
SVB Securities LLC
Cowen
Mizuho Securities
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW